Open an account

9 Meters Biopharma

NMTRQ · OTC

$0.00+$0.00 (+0.00%)TodayMarket open · · Delayed 15 min
No price history for this range.

About NMTRQ

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on unmet needs in gastroenterology. The company is headquartered in Raleigh, North Carolina and currently employs 10 full-time employees. The company went IPO on 2016-07-08. The firm has filed a voluntary petition for relief under provisions of Chapter 7 of Title 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the Eastern District of North Carolina.

Employees
10
Headquarters
Raleigh, North Carolina
Listed
Jul 8, 2016
Sector
Health Care
Industry
Pharmaceuticals
Website
9meters.com

NMTRQ key statistics

Market cap
14
Price-earnings ratio
-0.00
Dividend yield
—
Average volume
3.19K
Volume
3.00K
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.0005
52 Week low
$0.00

9 Meters Biopharma (NMTRQ) at a glance

As of Oct 19, 2026, 9 Meters Biopharma (NMTRQ) shares are priced at $0.00, giving the company a market cap of 14 and a price-to-earnings ratio of 0.00.

Volume so far is 3.00K shares, in line with the average of 3.19K shares a day.

Over the past year 9 Meters Biopharma has ranged from $0.00 to $0.0005, and now sits 0% of the way up that range.

9 Meters Biopharma met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q1 FY23 it reported -$1.02 per share against an estimate of -$0.8013.

NMTRQ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 8.2% on average.

  1. Q2 FY21: reported -$0.60 per share against an estimate of -$0.618
  2. Q3 FY21: reported -$1.00 per share against an estimate of -$0.7554
  3. Q4 FY21: reported -$0.80 per share against an estimate of -$0.7416
  4. Q1 FY22: reported -$0.80 per share against an estimate of -$0.7725
  5. Q2 FY22: reported -$0.80 per share against an estimate of -$0.8584
  6. Q3 FY22: reported -$0.72 per share against an estimate of -$0.8446
  7. Q4 FY22: reported -$0.92 per share against an estimate of -$0.785
  8. Q1 FY23: reported -$1.02 per share against an estimate of -$0.8013

Similar companies

Companies in the same industry as 9 Meters Biopharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.